Lab Anim Res.  2011 Dec;27(4):353-356. 10.5625/lar.2011.27.4.353.

Angiotropic metastatic malignant melanoma in a canine mammary gland

• Yang HJ
• Lee EM
• Kim AY
• Lee EJ
• Hong IH
• Huh SO
• Jeong KS

• KMID: 1444970
• DOI: http://doi.org/10.5625/lar.2011.27.4.353

Abstract

An eleven-year-old spayed female Yorkshire Terrier presented with a sublumbar mass and upon ultrasonographic examination, was revealed to have a mammary gland tumor. Black to reddish colored masses, located in the visceral peritoneum of the sublumbar region was observed on laparotomy with masectomy of the right side. In the laparotomy, we observed reddish masses multifocally located in the serosal membrane of the large intestine. Histopathologic examination of the intestinal and abdominal mass showed highly invasiveness into the muscle and metastasis of melanocytic tumor cells through the blood vessels. The mammary glands showed abnormal hyperplasia of melanocytes, destruction of the normal glands by tumor cells and infiltration of some lymphocytes in the pool of melanocytic cells. We have identified a malignant melanoma containing an angiotumoral complex in which tumor cells occupied a pericytic location along the microvessels with intravasation determined by immunohistochemistry for S100 protein and protein kinase C-alpha. Histologic findings in this dog lead to a diagnosis of an angiotropic metastatic malignant melanoma.

Keyword

Canine; malignant melanoma; mammary gland; metastasis; S100 protein; protein kinase C-alpha

MeSH Terms

Animals
Blood Vessels
Dogs
Female
Humans
Hyperplasia
Immunohistochemistry
Intestine, Large
Laparotomy
Lymphocytes
Mammary Glands, Human
Melanocytes
Melanoma
Membranes
Microvessels
Muscles
Neoplasm Metastasis
Peritoneum
Protein Kinase C-alpha
Protein Kinase C-alpha

Figure

• 

  Figure 1 Histopathological findings of the most extensively invaded lesions, skin and mammary glands. (A) Primary invasive melanoma. Abnormal hyperplasia of melanocytes in the dermal layers with hyperactivated epidermis melanocytes. H&E stain. Scale bar=500 µm. (B) Primary invasive melanoma. Note melanoma cells closely opposed to the external surface of microvessel (inset); melanocytic tumor cells invaded into the dermal lymphatic follicle and are hyperpigmented in the dermal reticular layer and more deep layers. H&E Stain. Scale bar=200 µm, (inset, H&E stain; Scale bar=500 µm). (C) Mammary glands also heavily pigmented. Abnormal hyperplasia of melanocytes as well as invasiveness and destruction of normal mammary glands by spindle melanocytic tumor cells. H&E stain. Scale bar=500 µm. (D) Mammary glands also heavily pigmented. Normal mammary glands were invaded with destruction by tumor cells. Pleomorphic round cells arranged in sheets or clusters. H&E stain. Scale bar=200 µm. (E) Malignant melanoma of the peritoneum lesion. Invasiveness and metastasis of melanocytic tumor in abdominal connective tissue and blood vessels. H&E stain. Scale bar=500 µm. (F) Malignant melanoma of the peritoneum lesion. Epitheloid and fusiform neoplastic cells infiltration. H&E stain. Scale bar=200 µm. (G and H) Malignant melanoma of the large intestinal lesion. Invasiveness into the muscle and metastasis of melanocytic tumor cells through the blood vessels and lymphatic channels surrounding glandular ducts. H&E stain. Scale bar=500 µm (G) and 200 µm (H).

• 

  Figure 2 Immunohistochemical stain with antibody for vimentin, S100 and PKC-α. (A) Malignant melanoma of the skin. Vimentin expression of mononuclear epitheloid amelanotic melanoma cells. ABC method, Mayer's hematoxylin counterstain. Scale bar=200 µm. (B) Malignant melanoma of the skin. S100 protein immunoreactivity is detected in melanoma cells, which is surrounded by multiple S100-negative epitheloid-shaped cells. ABC method, Mayer's hematoxylin counterstain. Scale bar=50 µm. (C) Malignant melanoma of the skin. Immunodetection of PKC-α in metastatic malignant melanoma. PKC-α expression in the epithelium of microvessels and some peripheral tumor cells. ABC method, Mayer's hematoxylin counterstain. Scale bar=200 µm.

Reference

1. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol. 1979; 16(1):32–40. PMID: 462717.

2. Harvey HJ, MacEwen G, Braun D, Patnaik AK, Withrow SJ, Jongeward S. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc. 1981; 178(6):580–582. PMID: 7263464.

3. MacEwen EG, Patnaik AK, Harvey HJ, Hayers AA, Matus R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 1986; 4(5):397–402. PMID: 3801954.

4. Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace LW, Fard A, Kottler SJ. Reprospective study of 338 canine oral melanomas with clinical, histologic, and immunohistichemical review of 129 cases. Vet Pathol. 2000; 37(6):597–608. PMID: 11105949.

5. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol. 2002; 39(6):651–678. PMID: 12450197.

6. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Beqq CB, Aqarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17(9):2745–2751. PMID: 10561349.

7. Houghton AN, Meyers ML, Chapman PB. Medical treatment of metastatic melanoma. Surg Clin North Am. 1996; 76(6):1343–1354. PMID: 8977555.

8. Rassnick KM, Ruslander DM, Cotter SM, Al-sarraf R, Bruyette DS, Gamblin RM, Meleo KA, Moore AS. Use of carboplatin for treatment of dogs with malignant melanoma: 27 casses (1989-2000). J Am Vet Med Assoc. 2001; 218(9):1444–1448. PMID: 11345308.

9. Barnhill RL. The biology of melanoma micrometastases. Recent Results Cancer Res. 2001; 158:3–13. PMID: 11092028.

10. Lugassy C, Barnhill RL, Christensen L. Melanoma and extravascular migratory metastasis. J Cutan Pathol. 2000; 27(9):481. PMID: 11028822.

11. Lugassy C, Eyden BP, Christensen L, Escande JP. Angiotumoral complex in human malignant melanoma characterised by free laminin: ultrastructural and immunohistochemical observations. J Submicrosc Cytol Pathol. 1997; 29(1):19–28. PMID: 9066138.

12. Lugassy C, Dickersin GR, Christensen L, Karaoli T, LeCharpentier M, Escande JP, Barnhill RL. Ultrastructural and immunohistochemical studies of the periendothelial matrix in human melanoma: evidence for an amorphous matrix containing laminin. J Cutan Pathol. 1999; 26(2):78–83. PMID: 10082397.

13. Moreno A, Espanol I, Ramogosa V. Angiotropic malignant melanoma. Report of two cases. J Cutan Pathol. 1992; 19(4):325–329. PMID: 1430472.

14. Eisen D, Voorhees JJ. Oral melanoma and other pigmented lesions of the oral cavity. J Am Acad Dermatol. 1991; 24(4):527–537. PMID: 2033125.

15. Griffiths GL, Lumsden JH. Fine neddle aspiration cytology and histologic correlation in canine tumors. Vet Clin Pathol. 1984; 13(1):13–17. PMID: 15311390.

16. Kerr S, Going JJ. Angiocentric invasion by lentigo malignat melanoma. J Clin Pathol. 1994; 47(2):183–184. PMID: 8132839.

17. Shea CR, Kline MA, Lugo J, McNutt NS. Angiotropic metastatic malignant melanoma. Am J Dermatopathol. 1995; 17(1):58–62. PMID: 7695012.

18. Saluja A, Money N, Zivoney DI, Solomon AR. Angiotropic malignant melanoma: A rare pattern of local metastases. J Am Acad Dermatol. 2001; 44(5):829–832. PMID: 11312432.

19. Rabanal RH, Fondevila DM, Montane V, Domingo M, Ferrer L. Immunocytochemical diagnosis of skin tumours of the dog with special reference to undifferentiated types. Res Vet Sci. 1989; 47(1):129–133. PMID: 2475897.

20. Sandusky GE Jr, Carlton WW, Wightman KA. Immunohistochemial staining for S100 protein in the diagnosis of canine amelanotic melanoma. Vet Pathol. 1985; 22(6):577–581. PMID: 2417399.

21. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 1988; 334(6184):661–665. PMID: 3045562.

22. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther. 1993; 59(3):257–280. PMID: 8309991.

23. Denham DW, Franz MG, Denham W, Zervos EE, Gower WR Jr, Rosemurgy AS, Norman J. Directed antisense therapy confirms the role of protein kinase C-α in the tumorigenicity of pancreatic cancer. Surgery. 1998; 124(2):218–223. PMID: 9706141.

24. Gescher A. Towards selective pharmacological modulation of protein kinase C-opportunities for the development of novel anti-neoplastic agents. Br J Cancer. 1992; 66(1):10–19. PMID: 1637658.

25. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, Foster CS. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol. 1999; 154(1):137–144. PMID: 9916928.

26. Tan X, Liu YJ, Li JC, Pan JQ, Sun WD, Wang XL. Activation of PKC and pulmonary vascular remodelling in broilers. Res Vet Sci. 2005; 79(2):131–137. PMID: 15924930.

27. Lahn MM, Sundell KL. The role of protein kinase C-α (PKC-α) in melanoma. Melanoma Res. 2004; 14(2):85–89. PMID: 15057036.